One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
doi : 10.1200/JCO-25-00625
Volume 43(18) pgs. 2035-2138 June 20, 2025
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
doi : 10.1200/JCO-24-02355
Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.
doi : 10.1200/JCO-24-02057
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
doi : 10.1200/JCO-24-02007
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
doi : 10.1200/JCO-25-00131
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes.
doi : 10.1200/JCO-24-02394
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.
doi : 10.1200/JCO-24-01865
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancerologie Digestive Database.
doi : 10.1200/JCO-24-01968
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.
doi : 10.1200/JCO.23.01965
Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD).
doi : 10.1200/JCO-24-02326
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
doi : 10.1200/JCO-25-00250
Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer.
doi : 10.1200/JCO-24-02207
Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer.
doi : 10.1200/JCO-24-02833
